Drug Database
DI

diltiazem (diltiazam, Aptalis / diltiazem, SURECAPS)

✓ Approved

Adare Pharma Solutions · CACNA1C · 小分子

什么是 diltiazem?

diltiazem 是一种小分子,由Adare Pharma Solutions研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名diltiazam, Aptalis, diltiazem, SURECAPS
公司Adare Pharma Solutions
药物类别小分子
分子靶点CACNA1C
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

diltiazem 作用于 1 个分子靶点:

CACNA1Ccalcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

diltiazem 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersAngina pectoris✓ Approved

相关研究文献

PubMedBMC cardiovascular disorders2026-11-19

Sleeping with the unknown: coronary vasospasm in an anomalous right circumflex artery mimicking in-stent restenosis.

Ali Fahad F, Kelly Jordan J, Karar Mohamed M, Elzain Hassan H et al.

Coronary vasospasm represents a transient, reversible constriction of coronary arteries that often goes unrecognised in patients with established coronary artery disease or anomalous coronary anatomy. When combined with prior percutaneous coronary intervention (PCI), vasospasm can closely mimic in-stent restenosis, leading to delayed diagnosis and unnecessary repeat interventions. We describe a 55-year-old male with prior PCI to an anomalous right circumflex artery (RCx) who presented with recurrent nocturnal chest pain and asymptomatic transient ST-segment elevation (STE) during sleep. Despite FFR-guided PCI to the left anterior descending artery (LAD) and subsequent repeat intervention for suspected RCx in-stent restenosis, symptoms persisted. A probable diagnosis of nocturnal coronary vasospasm was established based on the clinical presentation, characteristic nocturnal ECG changes, response to diltiazem, and exclusion of alternative structural pathology on cardiac magnetic resonance imaging; however, the diagnosis remains inferential in the absence of invasive provocation testing. This case illustrates the diagnostic complexity of probable coronary vasospasm in a male patient with structural coronary disease and anomalous coronary anatomy. Several factors may have contributed to diagnostic delay, including anchoring toward structural disease, angiographic ambiguity, anomalous anatomy, and the unusual nocturnal presentation. The differential response to calcium channel blocker subclasses in this patient is presented as a clinically relevant, hypothesis-generating observation rather than evidence of therapeutic superiority. Clinicians should maintain a high index of suspicion for probable coronary vasospasm in patients with recurrent nocturnal ST elevation following PCI, particularly when symptoms, telemetry findings, and coronary physiology are discordant with fixed obstructive disease. Careful reassessment, transparent acknowledgement of diagnostic uncertainty, and thoughtful use of non-invasive monitoring and targeted medical therapy may help avoid unnecessary repeat intervention.

PMID 43052750
阅读全文 →
PubMedCureus2026-10-17

Comparative Outcomes of Beta-Blockers vs Non-Dihydropyridine Calcium Channel Blockers in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

Othman Salman A SA, Alanazi Mansuor M, Aljuadi Saad F SF, Moeed Bushra B et al.

Determining the most effective medication regimen to manage blood pressure and heart rate in patients with heart failure with preserved ejection fraction (HFpEF) continues to lack a clear clinical consensus. Although beta-blockers (BBs) are widely prescribed, their negative chronotropic effects may worsen exercise intolerance. Alternative agents like verapamil and diltiazem, which belong to the non-dihydropyridine calcium channel blocker (non-DHP CCB) class, offer a physiological alternative, yet comparative data are scarce. A systematic review and meta-analysis were conducted, comparing BBs vs non-DHP CCBs in adults with HFpEF (left ventricular ejection fraction ≥ 50%). A literature search across key databases was conducted up until May 2026. Primary outcomes included all-cause mortality and heart failure (HF) hospitalization. Pooled hazard ratios (HRs) with 95% CIs were calculated using a random-effects analytical framework incorporating the Hartung-Knapp-Sidik-Jonkman variance correction. Evidence certainty was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Of the 576 retrieved records, two observational cohorts (106,848 patients) met the inclusion criteria. Only one of the two eligible cohorts analyzed real patient-level data; the other was generated. The two-study pooled estimates are reported as exploratory: all-cause mortality HR 0.88 (95% CI 0.34-2.26; p = 0.336) and HF hospitalization HR 0.91 (95% CI 0.34-2.42; p = 0.446), with I² > 80% for both outcomes. At k = 2, these dispersion statistics are themselves unstable, and the pooled intervals are not clinically interpretable. Restricted to the single real-world cohort, the estimates were HR 0.83 (95% CI 0.80-0.85) and HR 0.98 (95% CI 0.91-1.05), respectively, which are the figures of one observational study and carry no meta-analytic weight. Cardiovascular mortality, major adverse cardiovascular events, exercise capacity, and quality of life were prespecified but reported by neither study in poolable form. The confidence in these findings was rated as very low because the data stem from observational research and exhibit significant statistical variability alongside wide CIs. Current evidence does not demonstrate the prognostic superiority of either BBs or non-DHP CCBs in HFpEF. Given the very low certainty of the available data and high clinical heterogeneity, pharmacological selection should remain individualized. High-quality randomized controlled trials are needed to inform clinical guidelines.

PMID 42891286
阅读全文 →
PubMedJournal of molecular medicine (Berlin, Germany)2026-10-07

The calcium channel blocker diltiazem ameliorates parthanatos in juvenile neuronal ceroid lipofuscinosis.

Kim Hyungkuen H, Hwang Eunmi E, Kim Sung-Jo SJ

Accumulation of pre-mutagenic 8-oxoguanine and impaired DNA repair can lead to poly(ADP-ribose) (PAR) accumulation and parthanatos in Alzheimer's disease, the leading cause of age-dependent dementia. However, the occurrence of parthanatos has not been well established in other types of dementia, including juvenile neuronal ceroid lipofuscinosis (JNCL), a major form of juvenile dementia. In this study, we investigated parthanatos-associated pathology in JNCL using patient-derived lymphoblasts (PDLs). Quantitative immunofluorescence microscopy revealed increased accumulation of 8-oxoguanine and PAR in JNCL-PDLs. JNCL is known to exhibit elevated intracellular calcium, which activates PAR polymerase - 1 (PARP1). The L-type calcium channel blocker diltiazem effectively suppressed PAR accumulation in JNCL-PDLs, even under co-treatment with a calcium ionophore. Diltiazem also reduced 8-oxoG accumulation in JNCL-PDLs, although this effect was largely calcium independent. Subcellular fractionation followed by immunoblotting showed that diltiazem enhanced nuclear recruitment of OGG1 and its partner proteins. These protective effects were abolished by OGG1 knockdown, suggesting a dual role of diltiazem in regulating both calcium signaling and OGG1 activity. Collectively, our data identify that parthanatos as novel therapeutic target for JNCL and propose diltiazem as a potential therapeutic agent. KEY MESSAGES: Increased poly(ADP-ribose) accumulation represents a novel therapeutic target in juvenile neuronal ceroid lipofuscinosis caused by CLN3 mutations. Increased PARP1 expression and decreased PARP1 cleavage lead to elevated poly(ADP-ribose) accumulation in juvenile neuronal ceroid lipofuscinosis. Diltiazem ameliorates poly(ADP-ribose) accumulation in patient-derived cell models of juvenile neuronal ceroid lipofuscinosis by suppressing PARP1 expression and 8-oxoguanine accumulation.

PMID 42841989
阅读全文 →
PubMedEMBO molecular medicine2026-10-07

Small molecules rescue pathogenic POLGA aggregation and restore its functions in a mouse model of PEO.

Mohammed Aftab A, Kaur Tavleen T, Panwar Priyanka P, Ghosh Samanwita S et al.

POLGA, the catalytic subunit of the mitochondrial DNA polymerase, is essential for mitochondrial DNA (mtDNA) replication and maintenance. Mutations in POLGA cause progressive external ophthalmoplegia (PEO), but the underlying pathogenic mechanisms remain unclear. Here, we show that the mitochondrial E3 ligase MITOL hyperubiquitylates PEO-associated POLGA mutants at lysine 1060, triggering conformational changes and formation of insoluble aggregates that impair their mitochondrial import and consequently compromise mtDNA replication and mitochondrial homeostasis. To identify compounds that disrupt POLGA aggregates and restore mutant POLGA function, we screened an FDA/EMA/PMDA-approved drug library using a split-GFP system. We identified two clinically approved compounds, diltiazem hydrochloride (C1) and sulbactam (C4), that disrupted POLGA aggregates, prevented aberrant MITOL recognition, restored mitochondrial import, and rescued mtDNA replication and mitochondrial function. Importantly, treatment with either compound significantly improved motor performance in a knock-in mouse model carrying the disease-relevant A467T-equivalent POLGA mutation. These findings establish pathogenic aggregation as a previously underrecognized disease mechanism and demonstrate that disrupting POLGA aggregates with repurposed drugs can restore mitochondrial function in vivo, providing a potential therapeutic strategy for POLGA-associated mitochondrial disease.

PMID 42839124
阅读全文 →
PubMedPLoS pathogens2026-10-06

Targeting the Cav1.2-KCa1.1 axis prevents rabies virus internalization and protects against lethal infection.

Sun Ziruo Z, Wang Jinqiu J, Wen Zhiyuan Z, Shuai Lei L et al.

Rabies is an almost always fatal disease caused by rabies virus (RABV). Once RABV enters the central nervous system, the mortality rate is almost 100%. Therefore, preventing RABV from entering the nervous system is crucial for the development of anti-RABV therapeutics. Here, we found that the L-type calcium channel Cav1.2 pore-forming subunit (Cav1.2) and potassium calcium-activated channel subfamily M alpha 1 (KCa1.1) are involved in the internalization of RABV using an siRNA approach. RABV glycoprotein interacts with Cav1.2, a process that is required for the subsequent activation of the channel. The activated Cav1.2 then interacts with and activates KCa1.1 to regulate the endocytosis of RABV by promoting the F-actin polymerization. Importantly, diltiazem, a blocker of Cav1.2 and an FDA-approved drug, has been shown to substantially reduce mortality in mice infected with RABV. Approximately 70% of mice survived following treatment with diltiazem at 50 mg/kg, whereas the 25 mg/kg dose resulted in 26% survival. Our findings suggest that Cav1.2 is a promising target for the development of antiviral drugs against rabies and enhances our comprehension of the RABV entry mechanism.

PMID 42837418
阅读全文 →
PubMedFrontiers in pharmacology2026-10-06

Calcium channel blocker-associated pulmonary toxicity: epidemiology, mechanisms, and clinical management.

Jiang Qiu Q, Cui Wen-Hui WH, He Jia-Yi JY, Xie Zhi-Qi ZQ et al.

Calcium channel blockers are first-line medications for the treatment of hypertension, angina pectoris, and arrhythmias, and are generally well-tolerated. However, in recent years, there have been reports indicating that CCBs may cause severe pulmonary toxicity, such as non-cardiogenic pulmonary edema and acute respiratory distress syndrome. This article employs a comprehensive review methodology to systematically summarize the clinical types, incidence, risk factors, mechanisms of injury, and management strategies for CCB-related pulmonary toxicity. Current evidence indicates that pulmonary toxicity is extremely rare at standard therapeutic doses; however, the incidence increases significantly in cases of acute overdose and among specific populations (pregnant women, patients with underlying cardiopulmonary diseases). Pharmacovigilance studies have identified significant signals suggesting an association between nifedipine, diltiazem, and verapamil to pulmonary edema, with amlodipine having the highest number of related clinical reports. Major risk factors include drug overdose, pregnancy, underlying cardiopulmonary disease, and differences among CCB subclasses. Toxicity associated with dihydropyridine CCBs is primarily characterized by vasodilatory shock, whereas non-dihydropyridine CCBs exhibit a combination of cardiac depressant and vasodilatory effects. Mechanisms involve hemodynamic changes, increased capillary permeability, inflammatory activation, and alveolar epithelial dysfunction. Early recognition, drug discontinuation, selection of vasoactive agents based on the type of shock, and life support are key to improving prognosis.

PMID 42835333
阅读全文 →

注册免费账户还可查看另外 9159 篇文献

免费注册查看全部文献 →

了解更多diltiazem